Evidence map›Paper›PMID 36566200›Full record

ArticleBMC urology2022

Presence of secondary bladder cancer following radical nephroureterectomy for upper tract urothelial carcinoma: characteristics, risk factors, and predictive value.

Shicong Lai, Pengjie Wu, Shengjie Liu, Samuel Seery, Jianyong Liu, Lei He, Ming Liu, Yaoguang Zhang, Jian-Ye Wang, Tao Xu

Open access · goldAbstract read
In one paragraph

Article in BMC urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Shicong LaiDepartment of Urology, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing, 100044, China.
Pengjie WuDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, China.
Shengjie LiuDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, China.
Samuel SeerySchool of Humanities and Social Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Jianyong LiuGraduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Lei HeDepartment of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Ming LiuGraduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Yaoguang ZhangGraduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Jian-Ye WangGraduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China. wangjy@bjhmoh.cn.ORCID http://orcid.org/0000-0003-2172-6583
Tao XuDepartment of Urology, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing, 100044, China. xutao@pkuph.edu.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNPeking University · CN

Funding

Beijing Hospital Clinical Research BJ-2015-098Beijing Hospital Clinical Research 121 Project BJ-2018-090Beijing Municipal Science and Technology Project Z201100005620007National Key R&D Program of China 2018YFC2002202
6 · The paper itself

Abstract

backgroundTo assess the characteristics, predictive risk factors, and prognostic effect of secondary bladder cancer (SBCa) following radical nephroureterectomy (RNU) in upper tract urothelial carcinoma (UTUC).

methodsUsing the Surveillance, Epidemiology, and End Results database, the authors analyzed clinicopathologic characteristics and survival data from 472 UTUC patients with SBCa after RNU, between 2004 and 2017. Cox's proportional hazard regression model was implemented to identify independent predictors associated with post-recurrence outcomes. The threshold for statistical significance was p < 0.05.

resultsIn total, 200 Ta-3N0M0 localized UTUC patients with complete data were finally included. With a median follow-up of 71.0 months (interquartile ranges [IQR] 36.0 -103.8 months), 52.5% (n = 105) had died, with 30.5% (n = 61) dying of UTUC. The median time interval from UTUC to SBCa was 13.5 months (IQR 6.0-40.8 months). According to multivariable Cox regression analysis, patients with SBCa located at multiple sites, advanced SBCa stage, higher SBCa grade, elderly age and a shorter recurrence time, encountered worse cancer-specific survival (CSS), all p < 0.05.

conclusionFor primary UTUC patients with SBCa after radical surgery, advanced age, multiple SBCa sites, shorter recurrence time, higher SBCa stage, and grade proved to be significant independent prognostic factors of CSS. We ought to pay more attention to SBCa prevention as well as to earlier signs which may increase the likelihood of early detection. Having the ability to manage what may be seen as the superficial SBCa signs may enable us to improve survival but further research is required.

Indexed as

Carcinoma, Transitional CellUreteral NeoplasmsUrinary Bladder NeoplasmsAgedHumansNeoplasm Recurrence, LocalNephroureterectomyPrognosisRetrospective StudiesRisk FactorsCancer-specific survivalRadical nephroureterectomySecondary bladder cancer characteristicsUpper urinary tract urothelial carcinoma

Identifiers

PMID36566200
PMCPMC9789644
OpenAlexW4312119711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.